Terms: = Ovarian cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9
57 results:
1. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and ovarian cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract] [Full Text] [Related]
2. High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
Brzezinska B; Mysona DP; Richardson KP; Rungruang B; Hopkins D; Bearden G; Higgins R; Johnson M; Satter KB; McIndoe R; Ghamande S; Purohit S
Gynecol Oncol; 2023 Dec; 179():1-8. PubMed ID: 37862814
[TBL] [Abstract] [Full Text] [Related]
3. [Mechanism of Marsdenia tenacissima against ovarian cancer based on network pharmacology and experimental verification].
Hu YJ; Wei LY; Zhao J; Zhu QF; Meng ZY; Meng JJ; Chen JJ; Xu LY; Zhou YY; Han YL
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2222-2232. PubMed ID: 37282910
[TBL] [Abstract] [Full Text] [Related]
4. [Molecular mechanism of Spatholobi Caulis in treatment of ovarian cancer based on network pharmacology and experimental verification].
Zhu SC; Cai J; Wu CY; Cheng CS
Zhongguo Zhong Yao Za Zhi; 2022 Feb; 47(3):786-795. PubMed ID: 35178962
[TBL] [Abstract] [Full Text] [Related]
5. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in ovarian cancer Patients.
Zavarikina TM; Khokhlova SV; Tyulyandina AS; Khabas GN; Asaturova AV; Nosova YV; Brenner PK; Kapralova MA; Khodirev DS; Stenina MB
Bull Exp Biol Med; 2021 Oct; 171(6):755-759. PubMed ID: 34709513
[TBL] [Abstract] [Full Text] [Related]
6. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.
Huepenbecker SP; Sun CC; Fu S; Zhao H; Primm K; Giordano SH; Meyer LA
Cancer; 2021 Nov; 127(22):4151-4160. PubMed ID: 34347287
[TBL] [Abstract] [Full Text] [Related]
7. A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer.
Beachler DC; Lamy FX; Russo L; Taylor DH; Dinh J; Yin R; Jamal-Allial A; Dychter S; Lanes S; Verpillat P
J Ovarian Res; 2020 Aug; 13(1):101. PubMed ID: 32867806
[TBL] [Abstract] [Full Text] [Related]
8. Contribution of xeroderma pigmentosum complementation group D gene polymorphisms in breast and ovarian cancer susceptibility: A protocol for systematic review and meta analysis.
Tian Y; Lin X; Yang F; Zhao J; Yao K; Bian C
Medicine (Baltimore); 2020 May; 99(21):e20299. PubMed ID: 32481313
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive germline mutation analysis and clinical profile in a large cohort of Brazilian xeroderma pigmentosum patients.
Santiago KM; Castro LP; Neto JPD; de Nóbrega AF; Pinto CAL; Ashton-Prolla P; Pinto E Vairo F; de Medeiros PFV; Ribeiro EM; Ribeiro BFR; do Valle FF; Doriqui MJR; Leite CHB; Rocha RM; Moura LMS; Munford V; Galante PAF; Menck CFM; Rogatto SR; Achatz MI
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2392-2401. PubMed ID: 32239545
[TBL] [Abstract] [Full Text] [Related]
10. The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.
Zhao Z; Zhang A; Zhao Y; Xiang J; Yu D; Liang Z; Xu C; Zhang Q; Li J; Duan P
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29669843
[TBL] [Abstract] [Full Text] [Related]
11. Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.
Assis J; Pereira C; Nogueira A; Pereira D; Carreira R; Medeiros R
Cancer Treat Rev; 2017 Dec; 61():35-52. PubMed ID: 29100168
[TBL] [Abstract] [Full Text] [Related]
12. Association between ercc2 rs13181 polymorphism and ovarian cancer risk: an updated meta-analysis with 4024 subjects.
Li J; Pan L; Qin X; Chu H; Mu H; Wan G
Arch Gynecol Obstet; 2017 Sep; 296(3):551-558. PubMed ID: 28676967
[TBL] [Abstract] [Full Text] [Related]
13. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.
Li L; Bai H; Yang J; Cao D; Shen K
Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348
[TBL] [Abstract] [Full Text] [Related]
14. Association of R156R single nucleotide polymorphism of the ercc2 gene with the susceptibility to ovarian cancer.
Romanowicz H; Michalska MM; Samulak D; Malinowski J; Szaflik T; Bieńkiewicz J; Smolarz B
Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():36-40. PubMed ID: 27888704
[TBL] [Abstract] [Full Text] [Related]
15. Associations between XRCC2 rs3218536 and ercc2 rs13181 polymorphisms and ovarian cancer.
Zhang W; Zhang Z
Oncotarget; 2016 Dec; 7(52):86621-86629. PubMed ID: 27863412
[TBL] [Abstract] [Full Text] [Related]
16. Identification and Functional Testing of ercc2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and ovarian cancer.
Rump A; Benet-Pages A; Schubert S; Kuhlmann JD; Janavičius R; Macháčková E; Foretová L; Kleibl Z; Lhota F; Zemankova P; Betcheva-Krajcir E; Mackenroth L; Hackmann K; Lehmann J; Nissen A; DiDonato N; Opitz R; Thiele H; Kast K; Wimberger P; Holinski-Feder E; Emmert S; Schröck E; Klink B
PLoS Genet; 2016 Aug; 12(8):e1006248. PubMed ID: 27504877
[TBL] [Abstract] [Full Text] [Related]
17. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ercc2.
Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
[TBL] [Abstract] [Full Text] [Related]
18. Mutational analysis of FANCJ helicase.
Guo M; Vidhyasagar V; Talwar T; Kariem A; Wu Y
Methods; 2016 Oct; 108():118-29. PubMed ID: 27107905
[TBL] [Abstract] [Full Text] [Related]
19. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
[TBL] [Abstract] [Full Text] [Related]
20. Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.
Lambrechts S; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Smeets D; Debruyne PR; Renard V; Vroman P; Luyten D; Neven P; Amant F; Leunen K; Vergote I;
BMC Pharmacol Toxicol; 2015 Feb; 16():2. PubMed ID: 25881102
[TBL] [Abstract] [Full Text] [Related]
[Next]
